Figure 4
From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Patient discontinuation due to adverse events by cycle of romidepsin treatment in patients with relapsed/refractory peripheral or cutaneous T-cell lymphoma (PTCL, CTCL).